Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.

European journal of pharmacology - 5 Apr 2016

Mashkani Baratali, Tanipour Mohammad Hossein, Saadatmandzadeh Mohammad, Ashman Leonie K, Griffith Renate

Abstract excerpt

Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic target for small molecule kinase inhibitors. In this study, protein-ligand interactions between FLT3 and kinase inhibitors (CEP701, PKC412, sunitinib, imatinib and dasatinib) were obtained through homology modelling and molecular docking. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Molecular Docking Simulation

Share to Phosphorylation

Share to Protein Domains

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 26896780
DOI: 10.1016/j.ejphar.2016.02.048

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.PMID 26896780Read ↗

In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.Semantic proximity Read ↗

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.Semantic proximity Read ↗

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.Semantic proximity Read ↗

Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.Semantic proximity Read ↗

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.Semantic proximity Read ↗

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.Semantic proximity Read ↗

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.Semantic proximity Read ↗

Structure-Guided Discovery and Characterization of Novel FLT3 Inhibitors for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

Combined machine learning models, docking analysis, molecular dynamics and experimental validation for the rapid design of novel FLT3 inhibitors against AMLSemantic proximity Read ↗

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.Semantic proximity Read ↗

Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.Semantic proximity Read ↗

Flt3 receptor tyrosine kinase as a drug target in leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.